Antibodies beyond oncology at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
21 organizations at Antibody Engineering 2026 present work in beyond oncology: 13 drug developers, 6 academic, government and non-profit bodies and 2 suppliers and service providers. Between them they bring 28 presentations to the program. Most represented: Regeneron (3 on the program), argenx (2 on the program), Chugai Pharmaceutical (2 on the program). 7 of them have their own page in this guide. As of Sep 26, 2026.
Format
Top represented
Showing 1–17 of 21 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Regeneron Tarrytown, NY | |
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform. | Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Beyond oncology Talk Wed Dec 16 8:10am–8:15am |
Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy. | Talk Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Talk Wed Dec 16 4:15pm–4:45pm A Novel Antibody Approach to Pan-subclass IgG Reduction An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies. Beyond oncology |
Chugai Pharmaceutical Tokyo, Japan | |
Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies. | Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering |
Genmab Copenhagen, Denmark | |
Danish antibody company with marketed cancer medicines, developing bispecific antibodies and antibody-drug conjugates. | Talk Tue Dec 15 2:25pm–2:30pm Talk Wed Dec 16 11:30am–12:00pm Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces Reshaping the region where two antibody halves join, so several different antibodies can be made together in one mixture without mismatching. |
Harvard University Cambridge, MA | |
Private research university, including Harvard Medical School. | Talk Mon Dec 14 2:30pm–3:00pm Discovery of G protein-coupled Receptor Modulator Antibody Fragments Small antibody fragments that switch on or block the large family of signal-receiving proteins in cell membranes. Protein engineering Talk Wed Dec 16 8:15am–8:45am A New Homotypic Interface Expands Anti-Malarial Antibody Recognition Breadth Evolving a malaria antibody so copies of it grip each other in a new way and protect against more parasite strains. Beyond oncology |
University of Michigan Ann Arbor, MI | |
Public research university in Ann Arbor, Michigan. | Talk Sun Dec 13 1:00pm–1:15pm Talk Tue Dec 15 3:00pm–3:30pm Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration Antibodies that grab two receptors to cross into the brain and deliver gene-silencing strands into nerve cells. Bispecifics & multispecifics |
Commit Biologics Aarhus, Denmark | |
Aarhus University spin-out developing bispecific complement-engaging antibodies for cancer and autoimmune disease. | Keynote Mon Dec 14 9:15am–9:50am The Evolution of Antibody Therapies in Autoimmunity: From Toxic Immunosuppressant to Precision Modulator of Disease How antibody drugs for autoimmune disease moved from broadly damping the immune system to targeting single faulty pathways. Beyond oncology |
Hummingbird Bioscience Singapore | |
Develops antibody therapeutics and antibody-drug conjugates for cancer and autoimmune diseases. | Talk Wed Dec 16 5:15pm–5:45pm Novel, Next-generation ADCs for Autoimmune and Inflammatory Diseases How antibodies carrying a drug payload could be aimed at the immune cells driving inflammation, not just at cancer. Beyond oncology |
Incyte Wilmington, DE | |
Biopharmaceutical company discovering, developing and selling medicines in oncology and inflammation and autoimmunity. | Talk Tue Dec 15 5:45pm–6:15pm An Integrated Structure Biology Strategy for TCR Antibody Discovery Why the T-cell receptor is hard to target, and how high-resolution imaging of antibody binding sites guides better antibody choices. Protein engineering |
Independent biotech consulting practice. | Talk Tue Dec 15 2:25pm–2:30pm |
Merck Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics. | Talk Wed Dec 16 4:45pm–5:15pm uPAR Targeting Cytotoxic Antibody Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications Using single-cell data to pick a marker on inflammatory immune cells in rheumatoid arthritis, then killing those cells with a drug-carrying antibody. Beyond oncology |
Merida Biosciences Cambridge, MA | |
Develops Fc-based molecules that clear disease-causing autoantibodies for autoimmune and allergic diseases. | Talk Wed Dec 16 2:45pm–3:15pm FcyRIIB selective antigen-Fc fusion proteins enable selective neutralization, clearance, and B-cell inhibition of pathogenic autoantibodies Fusion proteins that mop up harmful self-attacking antibodies, pull them into cells for disposal, and quiet the B cells making them. Beyond oncology |
MT ModeX Therapeutics | |
OPKO Health company developing multispecific antibodies for cancer, infectious and immune diseases. | Talk Wed Dec 16 8:15am–8:45am Novel Multispecific Antibodies for Cancer and Immunological Diseases Antibody designs that bind several targets at once to treat cancer and immune diseases, with early laboratory examples. Beyond oncology |
Paradox Immunotherapeutics Toronto, Canada | |
Preclinical company developing antibodies that selectively target misfolded proteins, starting with AL and LECT2 amyloidosis. | Talk Tue Dec 15 5:15pm–5:45pm Beyond the Fold: Turning Protein Misfolding into Antibody Opportunity Antibodies that pick out the misfolded form of a protein and leave the healthy form alone, aimed at amyloid diseases. AI & computational design |
Sanofi Paris, France | |
Global pharmaceutical company developing medicines and vaccines, including antibodies for immunology and inflammatory diseases. | Talk Wed Dec 16 2:15pm–2:45pm The Bispecific and Multispecific Revolution in Antibody Therapeutics for Autoimmune and Inflammatory Diseases Why antibodies that hit two or more targets, so far mostly cancer drugs, are now being tried in autoimmune and inflammatory disease. Bispecifics & multispecificsBeyond oncology |
Technical University of Denmark Kongens Lyngby, Denmark | |
Danish technical university with research spanning engineering, biotechnology and health technology. | Keynote Mon Dec 14 8:40am–9:15am Snakebite Antivenoms En Route to Recombinant Biologics? How laboratory-made antibodies could replace plasma-derived antivenoms for snakebite, and what still blocks their use in patients. Antibody discoveryBeyond oncology |
The Hospital for Sick Children (SickKids) Toronto, Canada | |
Pediatric teaching hospital and research institute affiliated with the University of Toronto. | Talk Tue Dec 15 3:30pm–4:00pm Translating Multivalent Antibody Designs into Potent Viral Neutralizers Combining several antibodies into one molecule to neutralize varied viruses such as HIV, and what that does to blood levels. Bispecifics & multispecifics |
Instantly find 20 buyers in beyond oncology
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction